Literature DB >> 31391236

Bidirectional Cross-Talk between Biliary Epithelium and Th17 Cells Promotes Local Th17 Expansion and Bile Duct Proliferation in Biliary Liver Diseases.

Hannah C Jeffery1, Stuart Hunter1, Elizabeth H Humphreys1, Ricky Bhogal1, Rebecca E Wawman1,2, Jane Birtwistle3, Muhammad Atif1, Christopher J Bagnal4, Giovanny Rodriguez Blanco5, Naomi Richardson1, Suz Warner1,6, Warwick B Dunn5, Simon C Afford1, David H Adams1,7, Ye Htun Oo8,7.   

Abstract

There is no effective treatment for autoimmune biliary diseases. Therefore, understanding their immunopathology is crucial. The biliary epithelial cells (BEC), expressing TLR-4, are constantly exposed to gut microbes and bacterial wall LPS, and in settings of inflammation, the immune infiltrate is dense within the peribiliary region of human liver. By dual immunohistochemistry, we affirm human intrahepatic T cell infiltrate includes CCR6+CD4+ and AhR+CD4+ T cells with potential for plasticity to Th17 phenotype. Mechanistically, we demonstrate that Th1 and Th17 inflammatory cytokines and LPS enhance human primary BEC release of the CCR6 ligand CCL20 and BEC secretion of Th17-polarizing cytokines IL-6 and IL-1β. Cell culture assays with human BEC secretome showed that secretome polarizes CD4 T cells toward a Th17 phenotype and supports the survival of Th17 cells. BEC secretome did not promote Th1 cell generation. Additionally, we give evidence for a mutually beneficial feedback of the type 17 cell infiltrate on BEC, showing that treatment with type 17 cytokines increases BEC proliferation, as monitored by Ki67 and activation of JAK2-STAT3 signaling. This study identifies human BEC as active players in determining the nature of the intrahepatic immune microenvironment. In settings of inflammation and/or infection, biliary epithelium establishes a prominent peribiliary type 17 infiltrate via recruitment and retention and enhances polarization of intrahepatic CD4 cells toward Th17 cells via type 17 cytokines, and, reciprocally, Th17 cells promote BEC proliferation for biliary regeneration. Altogether, we provide new insight into cross-talk between Th17 lymphocytes and human primary biliary epithelium in biliary regenerative pathologies.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31391236      PMCID: PMC6697739          DOI: 10.4049/jimmunol.1800455

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

3.  TGF-beta, a 'double agent' in the immune pathology war.

Authors:  Daniel J Cua; Robert A Kastelein
Journal:  Nat Immunol       Date:  2006-06       Impact factor: 25.606

4.  TGFbeta1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells.

Authors:  Marc Veldhoen; Brigitta Stockinger
Journal:  Trends Immunol       Date:  2006-06-21       Impact factor: 16.687

5.  Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB.

Authors:  Xian-Ming Chen; Steven P O'Hara; Jeremy B Nelson; Patrick L Splinter; Aaron J Small; Pamela S Tietz; Andrew H Limper; Nicholas F LaRusso
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

6.  Increased expression of interleukin 17 in inflammatory bowel disease.

Authors:  S Fujino; A Andoh; S Bamba; A Ogawa; K Hata; Y Araki; T Bamba; Y Fujiyama
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

7.  Transforming growth factor-beta induces development of the T(H)17 lineage.

Authors:  Paul R Mangan; Laurie E Harrington; Darrell B O'Quinn; Whitney S Helms; Daniel C Bullard; Charles O Elson; Robin D Hatton; Sharon M Wahl; Trenton R Schoeb; Casey T Weaver
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

8.  Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis.

Authors:  Ai-Ping Wang; Kiyoshi Migita; Masahiro Ito; Yasushi Takii; Manabu Daikoku; Terufumi Yokoyama; Atsumasa Komori; Minoru Nakamura; Hiroshi Yatsuhashi; Hiromi Ishibashi
Journal:  J Autoimmun       Date:  2005-08       Impact factor: 7.094

9.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

10.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

View more
  7 in total

1.  Study protocol of Phase 2 open-label multicenter randomized controlled trial for granulocyte-colony stimulating factor (GCSF) in post-Kasai Type 3 biliary atresia.

Authors:  Hoa Pham Anh Nguyen; Jinma Ren; Marilyn Butler; Henri Li; Saqib Qazi; Kamran Sadiq; Hieu Trung Dao; AiXuan Holterman
Journal:  Pediatr Surg Int       Date:  2022-04-07       Impact factor: 1.827

Review 2.  The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.

Authors:  Lauren V Terry; Ye Htun Oo
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

Review 3.  Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy.

Authors:  Amber G Bozward; Vincenzo Ronca; Daniel Osei-Bordom; Ye Htun Oo
Journal:  Front Immunol       Date:  2021-08-25       Impact factor: 7.561

Review 4.  Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease.

Authors:  N Richardson; G E Wootton; A G Bozward; Y H Oo
Journal:  Semin Immunopathol       Date:  2022-05-31       Impact factor: 11.759

Review 5.  The Immunological Basis of Liver Allograft Rejection.

Authors:  Vincenzo Ronca; Grace Wootton; Chiara Milani; Owen Cain
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

Review 6.  Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease.

Authors:  Andrea Kristina Horst; Kingsley Gideon Kumashie; Katrin Neumann; Linda Diehl; Gisa Tiegs
Journal:  Cell Mol Immunol       Date:  2020-10-27       Impact factor: 11.530

Review 7.  The aryl hydrocarbon receptor in liver inflammation.

Authors:  Antonella Carambia; Fenja Amrei Schuran
Journal:  Semin Immunopathol       Date:  2021-06-01       Impact factor: 9.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.